Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Can we selectively target AML stem cells?

Jordan CT.

Best Pract Res Clin Haematol. 2019 Dec;32(4):101100. doi: 10.1016/j.beha.2019.101100. Epub 2019 Oct 18. Review.

PMID:
31779978
2.

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.

Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA.

Blood Adv. 2019 Oct 22;3(20):2911-2919. doi: 10.1182/bloodadvances.2019000243.

3.
4.

CD123 CAR T cells for the treatment of myelodysplastic syndrome.

Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E.

Exp Hematol. 2019 Jun;74:52-63.e3. doi: 10.1016/j.exphem.2019.05.002. Epub 2019 May 25.

5.

Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis.

Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldanek S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Meyers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, Jordan CT, Di Paola J, Hagman JR, Holers VM, Kuhn KA, Pietras EM.

Haematologica. 2019 May 17. pii: haematol.2018.197210. doi: 10.3324/haematol.2018.197210. [Epub ahead of print]

6.

Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II.

Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz JA, Pei S, Gustafson A, Khan N, DeGregori J, Pollyea DA, Jordan CT.

Blood. 2019 Jul 25;134(4):389-394. doi: 10.1182/blood.2019898114. Epub 2019 May 17.

PMID:
31101624
7.

Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.

Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, Jordan CT, Smith C, Pollyea DA.

Leuk Res. 2019 Jun;81:43-49. doi: 10.1016/j.leukres.2019.04.005. Epub 2019 Apr 13.

PMID:
31009835
8.

The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells.

Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, Siegenthaler J, Kume T, Campbell EL, Pollyea DA, Becker MW, Jordan CT.

Cell Rep. 2019 Apr 2;27(1):238-254.e6. doi: 10.1016/j.celrep.2019.03.009.

9.

Targeting Glutamine Metabolism and Redox State for Leukemia Therapy.

Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, Jordan CT, Hansen KC, D'Alessandro A, DeGregori J.

Clin Cancer Res. 2019 Jul 1;25(13):4079-4090. doi: 10.1158/1078-0432.CCR-18-3223. Epub 2019 Apr 2.

PMID:
30940653
10.

Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.

Pollyea DA, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, Jordan CT, Pietras EM, Alper S.

Haematologica. 2019 Sep;104(9):e388-e392. doi: 10.3324/haematol.2018.214155. Epub 2019 Mar 7. No abstract available.

11.

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.

Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, Jordan CT.

Cancer Cell. 2019 Feb 11;35(2):333-335. doi: 10.1016/j.ccell.2019.01.013. No abstract available.

12.

Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?

Pollyea DA, Jordan CT.

Curr Opin Hematol. 2019 Mar;26(2):71-76. doi: 10.1097/MOH.0000000000000485.

PMID:
30652974
13.

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.

Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, Jordan CT.

Cancer Cell. 2018 Nov 12;34(5):724-740.e4. doi: 10.1016/j.ccell.2018.10.005. Erratum in: Cancer Cell. 2019 Feb 11;35(2):333-335.

14.

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.

Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT.

Nat Med. 2018 Dec;24(12):1859-1866. doi: 10.1038/s41591-018-0233-1. Epub 2018 Nov 12.

PMID:
30420752
15.

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.

Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK.

JCI Insight. 2018 Nov 2;3(21). pii: 97941. doi: 10.1172/jci.insight.97941.

16.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

17.

Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells.

Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, Pollyea DA, Lozupone CA, Serkova NJ, Colgan SP, Jordan CT.

Cancer Cell. 2018 Oct 8;34(4):659-673.e6. doi: 10.1016/j.ccell.2018.08.016. Epub 2018 Sep 27.

18.

Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes.

Stevens BM, Khan N, D'Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, Pollyea DA, Jordan CT.

Nat Commun. 2018 Sep 12;9(1):3694. doi: 10.1038/s41467-018-05984-x.

19.

MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells.

Janganati V, Ponder J, Balasubramaniam M, Bhat-Nakshatri P, Bar EE, Nakshatri H, Jordan CT, Crooks PA.

Eur J Med Chem. 2018 Sep 5;157:562-581. doi: 10.1016/j.ejmech.2018.08.010. Epub 2018 Aug 10.

20.

AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells.

Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, Pollyea DA, Smith CA, Jordan CT.

Cell Stem Cell. 2018 Jul 5;23(1):86-100.e6. doi: 10.1016/j.stem.2018.05.021. Epub 2018 Jun 14.

21.

Reducible disulfide poly(beta-amino ester) hydrogels for antioxidant delivery.

Lakes AL, Jordan CT, Gupta P, Puleo DA, Hilt JZ, Dziubla TD.

Acta Biomater. 2018 Mar 1;68:178-189. doi: 10.1016/j.actbio.2017.12.030. Epub 2017 Dec 28.

22.

The environmental pollutant, polychlorinated biphenyls, and cardiovascular disease: a potential target for antioxidant nanotherapeutics.

Gupta P, Thompson BL, Wahlang B, Jordan CT, Zach Hilt J, Hennig B, Dziubla T.

Drug Deliv Transl Res. 2018 Jun;8(3):740-759. doi: 10.1007/s13346-017-0429-9. Review.

23.

A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia.

Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC.

Mol Cancer Ther. 2017 Oct;16(10):2058-2068. doi: 10.1158/1535-7163.MCT-16-0660. Epub 2017 Jun 27.

24.

Succinamide derivatives of melampomagnolide B and their anti-cancer activities.

Janganati V, Ponder J, Thakkar S, Jordan CT, Crooks PA.

Bioorg Med Chem. 2017 Jul 15;25(14):3694-3705. doi: 10.1016/j.bmc.2017.05.008. Epub 2017 May 8.

25.

Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells.

Bommagani S, Ponder J, Penthala NR, Janganati V, Jordan CT, Borrelli MJ, Crooks PA.

Eur J Med Chem. 2017 Aug 18;136:393-405. doi: 10.1016/j.ejmech.2017.05.031. Epub 2017 May 11.

26.

Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1.

Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea DA, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, Jordan CT, Smith CA.

Haematologica. 2017 Jun;102(6):1054-1065. doi: 10.3324/haematol.2016.159053. Epub 2017 Mar 9.

27.

Therapeutic targeting of acute myeloid leukemia stem cells.

Pollyea DA, Jordan CT.

Blood. 2017 Mar 23;129(12):1627-1635. doi: 10.1182/blood-2016-10-696039. Epub 2017 Feb 3. Review.

PMID:
28159738
28.

Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia.

Albayati ZAF, Janganati V, Chen Z, Ponder J, Breen PJ, Jordan CT, Crooks PA.

Bioorg Med Chem. 2017 Feb 1;25(3):1235-1241. doi: 10.1016/j.bmc.2016.12.036. Epub 2016 Dec 26.

29.

Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells.

Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT.

J Biol Chem. 2016 Nov 25;291(48):25280. No abstract available.

30.

ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.

Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, DeGregori J.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6669-E6678. Epub 2016 Oct 10.

31.

Design, synthesis and evaluation of anti-CD123 antibody drug conjugates.

Li B, Zhao W, Zhang X, Wang J, Luo X, Baker SD, Jordan CT, Dong Y.

Bioorg Med Chem. 2016 Nov 15;24(22):5855-5860. doi: 10.1016/j.bmc.2016.09.043. Epub 2016 Sep 17.

32.

Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells.

Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT.

J Biol Chem. 2016 Oct 14;291(42):21984-22000. Epub 2016 Aug 29. Erratum in: J Biol Chem. 2016 Nov 25;291(48):25280.

33.

Controlled curcumin release via conjugation into PBAE nanogels enhances mitochondrial protection against oxidative stress.

Gupta P, Jordan CT, Mitov MI, Butterfield DA, Hilt JZ, Dziubla TD.

Int J Pharm. 2016 Sep 25;511(2):1012-21. doi: 10.1016/j.ijpharm.2016.07.071. Epub 2016 Aug 2.

34.

Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.

Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW.

Blood. 2016 Sep 29;128(13):1671-8. doi: 10.1182/blood-2016-02-695312. Epub 2016 Jul 15.

35.

Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.

Tyagi V, Alwaseem H, O'Dwyer KM, Ponder J, Li QY, Jordan CT, Fasan R.

Bioorg Med Chem. 2016 Sep 1;24(17):3876-3886. doi: 10.1016/j.bmc.2016.06.028. Epub 2016 Jun 16.

36.

Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche.

Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, Jordan CT.

Cell Stem Cell. 2016 Jul 7;19(1):23-37. doi: 10.1016/j.stem.2016.06.001. Epub 2016 Jun 30.

37.

Acute myeloid leukaemia.

Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC.

Nat Rev Dis Primers. 2016 Mar 10;2:16010. doi: 10.1038/nrdp.2016.10. Review.

PMID:
27159408
38.

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.

Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK.

JCI Insight. 2016 Mar;1(3):e85630. doi: 10.1172/jci.insight.85630.

39.

MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.

Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM.

J Clin Invest. 2016 Apr 1;126(4):1438-50. doi: 10.1172/JCI80825. Epub 2016 Feb 29.

40.

SomVarIUS: somatic variant identification from unpaired tissue samples.

Smith KS, Yadav VK, Pei S, Pollyea DA, Jordan CT, De S.

Bioinformatics. 2016 Mar 15;32(6):808-13. doi: 10.1093/bioinformatics/btv685. Epub 2015 Nov 20.

PMID:
26589277
41.

Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells.

Janganati V, Ponder J, Jordan CT, Borrelli MJ, Penthala NR, Crooks PA.

J Med Chem. 2015 Nov 25;58(22):8896-906. doi: 10.1021/acs.jmedchem.5b01187. Epub 2015 Nov 16.

42.

Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series.

Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA.

Leuk Lymphoma. 2016;57(4):927-34. doi: 10.3109/10428194.2015.1094697. Epub 2015 Oct 27.

43.

CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts.

Ammar M, Jordan CT, Cao L, Lim E, Bouchlaka Souissi C, Jrad A, Omrane I, Kouidhi S, Zaraa I, Anbunathan H, Mokni M, Doss N, Guttman-Yassky E, El Gaaied AB, Menter A, Bowcock AM.

Br J Dermatol. 2016 Feb;174(2):330-7. doi: 10.1111/bjd.14158. Epub 2015 Nov 17.

44.

Micelle Delivery of Parthenolide to Acute Myeloid Leukemia Cells.

Baranello MP, Bauer L, Jordan CT, Benoit DSW.

Cell Mol Bioeng. 2015 Sep;8(3):455-470. Epub 2015 Apr 25.

45.

Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics.

Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, Levy JM, Pollyea DA, Jordan CT, Yan P, Frankhouser D, Nicolet D, Maharry K, Marcucci G, Choi KS, Cho H, Thorburn A, Kim YS.

Cell Res. 2015 Jun;25(6):707-25. doi: 10.1038/cr.2015.56. Epub 2015 May 8.

46.

Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.

Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, Earp HS, Graham DK.

Oncotarget. 2015 Mar 30;6(9):6722-36.

47.

A test of homogeneity for age-dependent branching processes with immigration.

Hyrien O, Yanev NM, Jordan CT.

Electron J Stat. 2015;9(1):898-925. Epub 2015 May 22.

48.

Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.

Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, DeGregori J.

Clin Cancer Res. 2015 Mar 15;21(6):1360-72. doi: 10.1158/1078-0432.CCR-14-2146. Epub 2014 Dec 29.

49.

Protein kinase C-associated kinase regulates NF-κB activation through inducing IKK activation.

Kim SW, Schifano M, Oleksyn D, Jordan CT, Ryan D, Insel R, Zhao J, Chen L.

Int J Oncol. 2014 Oct;45(4):1707-14. doi: 10.3892/ijo.2014.2578. Epub 2014 Aug 4.

PMID:
25096806
50.

Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.

Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT.

Haematologica. 2014 Aug;99(8):1277-84. doi: 10.3324/haematol.2013.085209. Review.

Supplemental Content

Loading ...
Support Center